Items tagged with "MAT"


publications  |   Probation Clients’ Barriers to Access and Use of Opioid Use Disorder Medications

Published: July 2, 2019
Some probationers with opioid use disorders (OUDs) cannot access medications to treat their disorders—methadone, buprenorphine, and naltrexone—which have been FDA-approved and proven-effective. This article shared finding from a survey of 26 Illinois probation department directors on how probation departments respond to clients with OUDs, focusing on the barriers to accessing OUD medications. The article noted that a majority of probation department leaders perceived barriers for probation client access to OUD medications including lack of medical personnel experience, cost, need for guidance on medications, and regulations prohibiting medication use. The article highlighted a need for training, interagency collaboration, and policy changes to increase access to, education on, and use of, medications for probation clients. Such efforts may result in positive outcomes such as reduced recidivism, increased quality of life, and reduced mortality.



articles  |   Probation Clients’ Barriers to Access and Use of Opioid Use Disorder Medications

Published: June 17, 2019
Some individuals on probation who have opioid use disorders (OUDs) cannot access effective, FDA-approved medications-methadone, buprenorphine, and naltrexone-to treat their disorders. This article shared finding from a survey of 26 Illinois probation department directors on how probation departments respond to clients with OUDs, focusing on the barriers to accessing OUD medications. The article noted that a majority of probation department leaders perceived barriers for probation client access to OUD medications including lack of medical personnel experience, cost, need for guidance on medications, and regulations prohibiting medication use. The article highlighted a need for training, interagency collaboration, and policy changes to increase access to, education on, and use of, medications for probation clients. Such efforts may result in positive outcomes such as reduced recidivism, increased quality of life, and reduced mortality.



publications  |   Addressing Opioid Use Disorders in Community Corrections: A Survey of Illinois Probation Departments

Published: October 26, 2018
Nearly one-third of Illinois probationers suffer from an opioid use disorder (OUD). Despite evidence that FDA-approved medications—methadone, buprenorphine, and naltrexone—can effectively treat OUD, many probation departments do not allow their clients to use them, even when prescribed by a healthcare provider. ICJIA researchers surveyed probation departments across the state to better understand their familiarity with, and training on, the medications, as well as barriers to their clients’ access and use. This article summarizes the study’s findings.



articles  |   Addressing Opioid Use Disorders in Community Corrections: A Survey of Illinois Probation Departments

Published: October 26, 2018
Nearly one-third of Illinois probationers suffer from an opioid use disorder (OUD). Despite evidence that FDA-approved medications—methadone, buprenorphine, and naltrexone—can effectively treat OUD, many probation departments do not allow their clients to use them, even when prescribed by a healthcare provider. ICJIA researchers surveyed probation departments across the state to better understand their familiarity with, and training on, the medications, as well as barriers to their clients’ access and use. This article summarizes the study’s findings.



articles  |   Addressing Opioid Use Disorders in Corrections: A Survey of Illinois Jails

Published: September 7, 2018
Even with substantial efforts at the state and local levels, opioid overdoses in Illinois continue to rise. Many in jails and prisons suffer from opioid use disorders and some receive treatment. Upon release, the risk of overdose is enhanced due to reduced tolerance. This article presents findings from a survey of 36 Illinois jail administrators on the use of medication-assisted treatment for detainees with opioid use disorders, naloxone distribution to reduce post-release overdose, and policies to ensure safe withdrawal from opioids and other drugs.



publications  |   Addressing Opioid Use Disorders in Corrections: A Survey of Illinois Jails

Published: September 7, 2018
Even with substantial efforts at the state and local levels, opioid overdoses in Illinois continue to rise. Many in jails and prisons suffer from opioid use disorders and some receive treatment. Upon release, the risk of overdose is enhanced due to reduced tolerance. This article presents findings from a survey of 36 Illinois jail administrators on the use of medication-assisted treatment for detainees with opioid use disorders, naloxone distribution to reduce post-release overdose, and policies to ensure safe withdrawal from opioids and other drugs.



publications  |   An Overview of Medication- Assisted Treatment for Opioid Use Disorders for Criminal Justice-Involved Individuals

Published: July 24, 2017
There is a national opioid epidemic and one intervention to help those suffering from an opioid use disorder (OUD) is medication-assisted treatment (MAT). MAT is the use of medications in conjunction with behavioral therapy as part of a long-term treatment regimen. There are three main MAT medications used today—methadone, buprenorphine, and naltrexone. Research has shown MAT, in particular the use of methadone or buprenorphine, is considered an evidence-based practice to treat OUD. Studies indicate those in MAT have better outcomes than those who engage in therapy alone. This article provides an overview of MAT with a focus on use with criminal justice populations.



articles  |   An Overview of Medication-Assisted Treatment for Opioid Use Disorders for Criminal Justice-Involved Individuals

Published: July 18, 2017
There is a national opioid epidemic and one intervention to help those suffering from an opioid use disorder (OUD) is medication-assisted treatment (MAT). MAT is the use of medications in conjunction with behavioral therapy as part of a long-term treatment regimen. There are three main MAT medications used today—methadone, buprenorphine, and naltrexone. Research has shown MAT, in particular the use of methadone or buprenorphine, is considered an evidence-based practice to treat OUD. Studies indicate those in MAT have better outcomes than those who engage in therapy alone. This article provides an overview of MAT with a focus on use with criminal justice populations.